JPRN-jRCTs071190003进行中（未招募）2 期
A prospective study of investigating the efficacy of FOLFIRI plus Aflibercept as a 2nd line therapy after progression during FOLFOXIRI plus Bevacizumab in unrescetable / metastatic colorectal cancer (CRC) patients. - EFFORT Study
Oki Eiji0 个研究点目标入组 35 人开始时间: 2019年4月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Written informed consent obtained from every patient before enrollment in the study.
- •2)The lead investigator deems that the patient can be treated according to the protocol (the patient is suitable for enrollment).
- •3)Patients with histologically confirmed advanced unresectable colorectal cancer (CRC) or metastatic CRC (mCRC).
- •4)RAS mutation status should be known. If possible BRAF mutation status as well.
- •5)Patients with unresectable CRC or mCRC who received FOLFOXIRI+bevacizumab as a first-line therapy. The reason for discontinuation of first line therapy is progressive disease (PD).
- •Patients with unresectable CRC or mCRC who discontinued first-line therapy with FOLFOXIRI+bevacizumab.
- •Patients who underwent adjuvant chemotherapy and FOLFOXIRI+bevacizumab treatment following recurrence. The date of recurrence confirmation should be at least 6 months from the final day of adjuvant therapy.
- •Patients who discontinued 5-FU/LV+bevacizumab as a maintenance therapy. FOLFOXIRI+bevacizumab as induction therapy will be administered for no more than 12 cycles.
- •Patients who underwent both induction therapy (FOLFOXIRI+bevaczizumab) and maintenance therapy (5-FU/LV+bevacizumab) are preferable to this study.
- •6)Radiation therapy was not administered to the target lesion.
- •Patients who have received neoadjuvant or adjuvant radiation therapy will be included.
- •Patients who have received radiation therapy against non-target lesions will be included.
- •7)Aged >=20 years
- •8)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- •Patients with unresectable CRC or mCRC who discontinued first-line therapy with FOLFOXIRI+bevacizumab.
- •Patients who underwent adjuvant chemotherapy and FOLFOXIRI+bevacizumab treatment following recurrence. The date of recurrence confirmation should be at least 6 months from the final day of adjuvant therapy.
- •Patients who discontinued 5-FU/LV+bevacizumab as a maintenance therapy. FOLFOXIRI+bevacizumab as induction therapy will be administered for no more than 12 cycles.
- •Patients who underwent both induction therapy (FOLFOXIRI+bevaczizumab) and maintenance therapy (5-FU/LV+bevacizumab) are preferable to this study.
- •6)Radiation therapy was not administered to the target lesion.
- •Patients who have received neoadjuvant or adjuvant radiation therapy will be included.
- •Patients who have received radiation therapy against non-target lesions will be included.
- •7)Aged >=20 years
- •8)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- •9)Measurable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, version 1.1. Imaging should be performed within 28 days prior to enrolment
- •Measurable lesions should be 10 mm or more on the major axis using a CT scan with a 5 mm slice. For metastatic lymph nodes, the minor axis should exceed 15 mm in length.
- •10)Patient who have enough oral ingestion.
- •11)Patients must have no severe dysfunction of major organs.
- •WBC>=3,000 cells/mm^3, =<12,000/mm^3
- •Neutrophil count>=1,500 cells/mm^3
- •Platelet count>=75,000 cells/mm^3
- •Hemoglobin>=9.0 g/dL
- •Total bilirubin<=1.5 mg/dL
- •AST (GOT)<=100 IU/L or <=200 IU/L in patients with liver metastases
- •ALT (GPT)<=100 IU/L or <=200 IU/L in patients with liver metastases
- •Creatinine <1.5 mg/dL
- •Creatinine clearance (CCr)>=50 mL/min
- •Protein urea Grade <=1(1+ or <1.0 g/24 h)
- •UGT1A1 wild-type or UGT1A1*6, or UGT1A1*28 polymorphisms
- •12)Life expectancy>= 3 months
排除标准
- •1)Patients with hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) that cannot be adequately controlled with 2 antihypertensive agents*.
- •*One antihypertensive treatment containing two antihypertensive agents counts as two antihypertensives.
- •Patients with diabetes mellitus that cannot be adequately controlled with medication.
- •Patients with heart disease that may cause problems, such as congestive heart failure, angina pectoris requiring medication, clear evidence of transmural myocardial infarction on an ECG, clinically evident valvular heart disease, symptomatic coronary disease, poorly controlled arrhythmia, and a previous history of myocardial infarction within the last 12 months..
- •2)Patients with severe pulmonary disease, including interstitial pneumonia, pulmonary fibrosis and severe emphysema.
- •3)Patients with an active infection.
- •4)Patients with clinically significant ascites and pleural effusion.
- •5)Patients who have severe drug hypersensitivity (particularly to 5-FU, irinotecan, or aflibercept).
- •6)Patients with active multiple cancers. Synchronous double cancer and metachronous double cancer within a disease-free interval of 5 years. Lesions consistent with carcinoma in situ or intramucosal carcinoma that have been cured by local treatment are not classified as active multiple cancers.
- •7)Patients with a psychiatric disorder that may pose a problem, or a history of central nervous system dysfunction.
- •8)Patients who have brain metastases, or where brain metastases are possible.
- •9)Patients who have had a gastrointestinal perforation and/or a gastrointestinal fistula up to 6 months prior to enrollment.
- •10)Watery diarrhea or diarrhea Grade >=2
- •11)Patients who have had deep vein thrombosis, pulmonary embolism, or some other major form of thromboembolism (portal vein or catheter thrombosis and superficial venous thrombosis qualify as major forms) up to 3 months prior to enrollment.
- •12)The patient has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to the first dose of protocol therapy.
- •13)Daily treatment with high-dose aspirin (>=325 mg/day).
- •14)Non-steroidal anti-inflammatory medications and immune suppressive or steroidal medications.
- •15)Patients receiving phenytoin, warfarin potassium, or flucytosine.
- •16)Women who are pregnant, breast feeding, or who wish to conceive.
- •17)Men who wish to conceive.
- •18)Patients with active gastrointestinal tract bleeding requiring repeated transfusions.
- •19)Patient who underwent resection after FOLFOXIRI+bevacizumab because of conversion and had progressed.
- •20)Patient who unable to tolerate aflibercept, 5-FU or irinotecan.
- •21)Patient with a severe stenosis due to primary CRC. Primary patient with CRC resection or colostomy can be included.
- •22)Patients with hepatic cirrhosis or active hepatitis.
- •23)Patients whom a lead investigator or primary physician deems are not appropriate for this study.
研究者
相似试验
招募中
不适用
A prospective study to evaluate the efficacy and safety of pregabalin for triweekly abraxane-induced peripheral neuralgiaBreast cancerJPRN-UMIN000006987Kinki University Faculty of Medicine30
招募中
不适用
A prospective study to evaluate the efficacy and safety of a new knife in endoscopic treatment for gastric neoplasmNeoplasmsKCT0005164Asan Medical Center100
已完成
不适用
A prospective study investigating the efficacy and safety of traction-band-assisted endoscopic closure for mucosal defect after colorectal endoscopic submucosal dissection: A multi-center trial (TBEC Trial)Colorectal neoplasmsJPRN-UMIN000047953Kitakyushu Municipal Medical Center34
尚未招募
2 期
Chemoradiation and immunotherapy for unresectable skin squamous cell carcinomaskin cancersquamous cell carcinomaACTRN12618001573246Metro North Hospital and Health Service15
招募中
不适用
A prospective observational study on the efficacy of switching to sertraline in depressive patients who failed treatment with duloxetinemajor depressive disorderJPRN-UMIN000009609Tokyo Womens Medical University100